Kahn Brothers Cuts Merck & Co., Bristol-Myers

Firm's largest sales of the 3rd quarter

Author's Avatar
Nov 09, 2020
Article's Main Image

Investment firm Kahn Brothers (Trades, Portfolio) sold shares of the following stocks during the third quarter of fiscal 2020, which ended on Sept. 30.

Merck & Co.

The firm reduced its stake in Merck & Co. Inc. (MRK) by 13.21%. The trade had an impact of -1.60% on the portfolio.

The pharmaceutical products provider has a market cap of $203 billion and an enterprise value of $223 billion.

8fae6f5a935c4946a9f5237ed4b4e2dd.png

GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 42.9% and return on assets of 13.48% are outperforming 91% of companies in the drug manufacturers industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.36 is below the industry median of 0.87.

The company's largest guru shareholder is Ken Fisher (Trades, Portfolio) with 0.36% of outstanding shares, followed by Pioneer Investments (Trades, Portfolio) by 0.35% and Vanguard Health Care Fund (Trades, Portfolio) with 0.23%.

Bristol-Myers

The Bristol-Myers Squibb Company (BMY) position was trimmed by 7.86%, impacting the portfolio by -0.79%.

The company, which provides drugs for various indications such as cardiovascular, oncology and immune disorders, has a market cap of $144 billion and an enterprise value of $168 billion.

d329b37e38d2a613463ffa004c01af4b.png

GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of -0.1% and return on assets of -0.04% are underperforming 54% of companies in the drug manufacturers industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.47 is above the industry median of 0.87.

The largest guru shareholder of the company is Jim Simons (Trades, Portfolio)' Renaissance Technologies with 1.93% of outstanding shares, followed by Vanguard Health Care Fund (Trades, Portfolio) with 1.51% and Dodge & Cox with 1.27%.

GlaxoSmithKline

The firm cut its position in GlaxoSmithKline PLC (GSK) by 7.33%. The portfolio was impacted by -0.77%.

The company, which operates in the pharmaceutical industry, has a market cap of $92.42 billion and an enterprise value of $132.19 billion.

509ac297c057065cf93e63ebdc33c2b3.png

GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 49.66% and return on assets of 7.72% are outperforming 78% of companies in the drug manufacturers industry. Its financial strength is rated 4 out of 10. The cash-debt ratio of 0.16 is below the industry median of 0.87.

The largest guru shareholder is Dodge & Cox with 1.66% of outstanding shares, followed by Simons' firm with 0.82% and HOTCHKIS & WILEY with 0.29%.

Citigroup

The firm reduced its Citigroup Inc. (C) holding by 8.84%, impacting the portfolio by -0.71%.

The global financial services company has a market cap of $88.92 billion and an enterprise value of $194.62 billion.

e3a54982d4ab39e5f5cd89d72a477835.png

GuruFocus gives the company a profitability and growth rating of 4 out of 10. The return on equity of 5.6% and return on assets of -0.57% are underperforming 66% of companies in the banks industry. Its financial strength is rated 3 out of 10. The cash-debt ratio of 1.04 is below the industry median of 1.45.

The largest guru shareholder of the company is ValueAct Holdings LP (Trades, Portfolio) with 1.30% of outstanding shares, followed by HOTCHKIS & WILEY with 0.56% and Diamond Hill Capital (Trades, Portfolio) with 0.45%.

Seaboard

The investment firm trimmed its Seaboard Corp. (SEB) position by 10.25%. The trade had an impact of -0.63% on the portfolio.

The company has a market cap of $3.86 billion and an enterprise value of $3.99 billion.

fed35ebfa288dc81a2dfda10c1407b1a.png

GuruFocus gives the company a profitability and growth rating of 6 out of 10. The return on equity of 5.58% and return on assets of 3.19% are outperforming 64% of companies in the conglomerates industry. Its financial strength is rated 7 out of 10. The cash-debt ratio of 0.92 is above the industry median of 0.42.

The largest guru shareholder of the company is Kahn Brothers (Trades, Portfolio) with 0.96% of outstanding shares, followed by Simons' firm with 0.69% and Diamond Hill Capital (Trades, Portfolio) with 0.54%.

New York Community Bancorp

The investment firm reduced its New York Community Bancorp Inc. (NYCB) position by 6.57%. The trade had an impact of -0.58% on the portfolio.

The U.S.-based multi-bank holding company has a market cap of $3.62 billion and an enterprise value of $17.21 billion.

f40d44b6e4e2b5793d2c4d2385675975.png

GuruFocus gives the company a profitability and growth rating of 4 out of 10. The return on equity of 5.77% and return on assets of 0.78% are underperforming 65% of companies in the banks industry. Its financial strength is rated 2 out of 10. The cash-debt ratio of 0.09 is below the industry median of 1.45.

The largest guru shareholder of the company is Barrow, Hanley, Mewhinney & Strauss with 11.47% of outstanding shares, followed by Kahn Brothers (Trades, Portfolio) with 1.04% and Simons' firm with 0.28%.

Disclosure: I do not own any stocks mentioned.

Read more here:

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.